inactivated SARS-CoV-2 vaccine (COVID-19 Vaccine (Vero Cell) Inactivated)
/ Jiangsu Rec-Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 25, 2023
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
(clinicaltrials.gov)
- P2 | N=300 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Recruiting ➔ Completed | Phase classification: P2/3 ➔ P2
Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease
September 30, 2022
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
(clinicaltrials.gov)
- P2/3 | N=300 | Recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Active, not recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease
August 04, 2022
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
(clinicaltrials.gov)
- P2/3 | N=300 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | N=1950 ➔ 300 | Trial primary completion date: Feb 2023 ➔ Aug 2022
Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1